To compile this year's list, TIME solicited nominations from TIME editors and correspondents around the world through an online application process, paying special attention to growing fields—such as ...

Please provide your email address to receive an email when new articles are posted on . Levonorgestrel-releasing intrauterine system users vs. nonusers had an increased risk for breast cancer. Breast ...

SKYLA (levonorgestrel-releasing intrauterine system) Bayer HealthCare announced that the FDA has approved Skyla, a new hormone-releasing intrauterine system for the prevention of pregnancy for up to ...

ROSWELL, Ga., Feb. 25, 2025 /PRNewswire/ -- Sebela Women's Health Inc., a part of Sebela Pharmaceuticals, today announced that the U.S. Food and Drug Administration (FDA) granted approval of MIUDELLA ...

August 26, 2010 — For women with documented idiopathic heavy menstrual bleeding, the levonorgestrel-releasing intrauterine system is associated with a greater reduction in menstrual blood loss and a ...

Nearly half of all pregnancies in the United States are unin- tended,1 which is defined as any pregnancy either mistimed, unplanned, or unwanted.2,3 Prior studies on unintended preg- nancy in the ...

Levonorgestrel intrauterine system is safe and efficacious for contraception over a 5-year period, data from a phase III trial found. Pearl Indices, or the number of unintentional pregnancies, for ...

Women who use copper intrauterine devices (IUD) as a form of birth control may be at lower risk for high-grade cervical cancer compared with those who use a levonorgestrel-releasing intrauterine ...

Hazard ratios were 1.3, 1.4, and 1.8 for 0 to 5, 5 to 10, and more than 10 to 15 years of use, respectively, compared with the corresponding durations of nonuse, resulting in an excess of 14, 29, and ...

· Levosert is effective for 8 years in the contraception indication and has demonstrated efficacy for 3 years in the indication of heavy menstrual bleeding. 1 Therefore, Levosert should be removed or ...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, a leader in women's healthcare, announced today that the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) that ...

The MarketWatch News Department was not involved in the creation of this content. ROSWELL, Ga., Oct. 15, 2025 /PRNewswire/ -- Sebela Women's Health Inc., a part of Sebela Pharmaceuticals, today ...